High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
Hee Bok Chae, Mee Jin Kim, Eui Geun Seo, Yong Hyeok Choi, Hee Seung Lee, Joung Ho Han, Soon Man Yoon, Seon Mee Park, Sei Jin Youn
Korean J Hepatol. 2012;18(1):75-83.   Published online 2012 Mar 22     DOI: https://doi.org/10.3350/kjhep.2012.18.1.75
Citations to this article as recorded by Crossref logo
Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug–Drug Interactions
Jana Mandíková, Marie Volková, Petr Pávek, Lucie Navrátilová, Lucie Hyršová, Zlatko Janeba, Jan Pavlík, Pavel Bárta, František Trejtnar
Frontiers in Pharmacology.2016;[Epub]     CrossRef
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures
Qian Zhang, Tao Han, Cai-Yun Nie, Fu-Shuang Ha, Lei Liu, Hua Liu
Journal of Medical Virology.2015; 87(6): 1013.     CrossRef
Impact of Nucleos(t)ide Analogue Combination Therapy on the Estimated Glomerular Filtration Rate in Patients With Chronic Hepatitis B
Xun Qi, Jinyu Wang, Liang Chen, Yuxian Huang, Yanli Qin, Richeng Mao, Jiming Zhang
Medicine.2015; 94(15): e646.     CrossRef
Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B
Jeong Heo, Sang Hoon Ahn, Young-Oh Kweon, Byung-Ho Kim, Henry L Y Chan, Andrzej Horban, Suchat Wongcharatrawee, Cyril Llamoso, Kwan Sik Lee
Journal of Gastroenterology and Hepatology.2014; 29(7): 1485.     CrossRef
Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment
Xiaohong Wang, Changjiang Zhang, Yan Zhu, Yulin Xiong, Yuming Wang
Antiviral Research.2014; 103: 71.     CrossRef
Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B
Seong Hee Kang, Hyung Joon Yim, Hae Rim Kim, Keunhee Kang, Sang Jun Suh, Hyun Jung Lee, Eileen L. Yoon, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun
Journal of Clinical Gastroenterology.2014; : 1.     CrossRef
Management of antiviral drug resistance in chronic hepatitis B
Ki Bae Bang
World Journal of Gastroenterology.2014; 20(33): 11641.     CrossRef
Predictive Factors for Delayed Virologic Response of Adefovir Add-on Therapy in Lamivudine-resistant Chronic Hepatitis B
Ae Rin Baek, Dae Yong Kim, Young Seok Kim, Sang Gyune Kim, Jung Hyun Kim, Min Suk Kim, Tae Jin Kim, Yun Nah Lee, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
Soonchunhyang Medical Science.2013; 19(1): 10.     CrossRef
OAT1 and OAT3: Targets of drug–drug interaction between entecavir and JBP485
Qinghan Xu, Changyuan Wang, Qiang Meng, Qi Liu, Huijun Sun, Jinyong Peng, Xiaochi Ma, Taiichi Kaku, Kexin Liu
European Journal of Pharmaceutical Sciences.2013; 48(4-5): 650.     CrossRef
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
Hyung Joon Yim, Seong Gyu Hwang
Clinical and Molecular Hepatology.2013; 19(3): 195.     CrossRef
Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice
Xian-Hua Xu, Gai-Li Li, Yang Qin, Qiang Li, Fa-Qun He, Jin-Ye Li, Quan-Rong Pan, Jie-Yin Deng
Virology Journal.2013; 10(1): 162.     CrossRef